Table 1

Neutralization sensitivity of primary HIV-1 Envs with variable macrophage tropism to gp120 mAbs, soluble CD4, and a broadly neutralizing HIV-infected patient serum

Patient

Tissue^a

Env clone

MDM entry^b

b12 IC₅₀^c

b6 IC₅₀^c

sCD4 IC₅₀^c

PS IC₅₀^c

MACS2

FL

8–12

35478

3.37

> 20

1.03

80.9

9–15

1765

1.15

> 20

0.22

76.4

LN

10–15

13001

0.99

> 20

> 20

< 50

SP

6–18

59224

10.89

> 20

> 20

< 50

MACS3

FL

12–27

13810

> 20

1.87

1.10

< 50

5

3402

> 20

6.78

0.40

< 50

LN

2

1957

> 20

> 20

3.22

< 50

20

16658

> 20

> 20

> 20

< 50

UK1

FL

2–13b

4378

0.05

> 20

5.44

< 50

SP

6–20

812689

0.03

> 20

2.39

124.2

20

35723

0.03

> 20

0.27

230.2

UK7

FL

6–24

9659

5.53

> 20

7.68

145

1–4

13207

11.37

> 20

> 20

128

isolate

br34

496588

0.26

> 20

0.45

332.2

LN

7–6

5260

5.55

> 20

> 20

< 50

controls

YU2

38052

5.47

> 20

1.14

72.4

YU2 N386D

114755

2.79

> 20

0.45

115.2

JRFL

215305

0.18

> 20

3.72

107.3

JRFL N386D

320642

0.09

> 20

6.05

92.7

^a FL, frontal lobe (brain); LN, lymph node; SP, spleen

^b Luciferase activity in monocyte-derived macrophages (MDM) infected with pseudotyped luciferase-expressing reporter viruses [10,14].

^c mAb (μg/ml), soluble CD4 (sCD4; μg/ml), or HIV-infected patient serum (PS; reciprocal serum dilution) concentration at which luciferase expression was reduced by 50% compared to infection in the absence of mAb (IC₅₀).

Dunfee et al. Retrovirology 2009 6:69   doi:10.1186/1742-4690-6-69